Supira Medical Closes $30M Series C Funding
Summary
Supira Medical, a Los Gatos, CA-based Shifamed portfolio company focused on developing a next-generation solution for temporary mechanical circulatory support, raised $30M in Series C funding. The company intends to use the funds to finalize product development and initiate a first-in-human clinical study for its percutaneous ventricular assist device. Led by CEO Dr. Nitin Salunke, Supira Medical is focused on development of a next generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Percutaneous ventricular assist devices (pVADs) are used during stent placement or angioplasty to provide temporary mechanical support for high-risk patients with severe coronary artery disease or comorbidities. Additionally, pVADs are used to treat patients suffering from cardiogenic shock (CS), a condition that can occur following a severe heart attack, and is associated with a high rate of morbidity as a patient’s heart is suddenly too weak to adequately pump blood to vital organs.